SCHEDULE: SR One Entities Adjust Veradermics Stake

SR One Capital Management and affiliated entities have filed an amendment to their Schedule 13D, reporting a sale of Veradermics, Inc. common stock and adjusting their beneficial ownership.

Summary

• SR One Capital Management, LLC and its affiliated entities (collectively, the Reporting Persons) have filed an Amendment No. 1 to their Schedule 13D concerning Veradermics, Inc. common stock.
• This filing confirms a joint agreement for filing Schedule 13D and reports the sale of an aggregate of 321,749 shares of Veradermics, Inc. common stock by SR One Fund II Aggregator, LP and AMZL, LP.
• The sale occurred on August 12, 2026, in a privately negotiated transaction at $104.30 per share, totaling approximately $33,558,420.
• Following the sale, the Reporting Persons' aggregate beneficial ownership of Veradermics, Inc. common stock has decreased, with SR One Fund II Aggregator holding 1,403,959 shares (3.4%) and AMZL holding 676,160 shares (1.6%).
• The total shares held by the Funds after the sale are 2,080,119, representing 4.9% of the outstanding common stock as of August 6, 2026.
• The filing states that the Reporting Persons do not have any present plans for further acquisition or disposition of securities, extraordinary corporate transactions, sale of material assets, changes in management or board, or material changes in capitalization or dividend policy.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily concerns a procedural agreement for joint Schedule 13D filing and a sale of shares, without significant new strategic information or financial performance indicators.

Positives

• The sale was executed at a price of $104.30 per share, indicating a potentially favorable valuation at the time of the transaction.
• The Reporting Persons have clearly defined their beneficial ownership percentages after the sale, providing transparency to the market.
• The filing explicitly states no current plans for actions that could negatively impact the company's structure or operations, such as mergers, asset sales, or management changes.

Negatives

• A significant sale of shares by a major holder like SR One Capital Management could be interpreted as a lack of confidence or a strategic shift, potentially impacting investor sentiment.
• The aggregate sale amount of approximately $33.56 million represents a notable reduction in the Reporting Persons' stake.

Risks

• Depending on market conditions and other factors, the Funds may dispose of additional shares of the Issuer, which could lead to further downward pressure on the stock price.
• While no current plans are disclosed, future strategic decisions by the Reporting Persons could still impact the company.

Future Outlook

The filing explicitly states that, except as set forth in Item 4, none of the Reporting Persons has any present plans that relate to or would result in any of the listed actions, including acquisition or disposition of additional securities, extraordinary corporate transactions, sale of material assets, changes in management or board, or material changes in capitalization or dividend policy. However, it also notes that depending on market conditions and other factors, the Funds may dispose of additional shares.

Management Comments

• Simeon George, M.D., as Managing Member of SR One Capital Management, LLC, has signed the agreement and the Schedule 13D amendment, authorizing Sasha Keough as attorney-in-fact.
• The filing indicates that SR One Capital Management, LP, acts as the principal business entity for managing various investment funds.

Industry Context

StockSavvy.ai notes that this filing pertains to a Schedule 13D amendment, which is typically filed when an investor acquires more than 5% of a company's stock or makes significant changes to their holdings or intentions. The sale of shares by SR One, a venture capital firm, suggests a potential portfolio management decision or a rebalancing of their investment strategy. The price of $104.30 per share indicates a substantial valuation for Veradermics, Inc. at the time of the transaction.

Stakeholder Impact

• Shareholders may be impacted by the sale of a significant block of shares, potentially affecting stock price due to increased supply or perceived change in investor sentiment.
• The company's management and board may need to address potential market perceptions arising from the reduction in beneficial ownership by SR One.

Next Steps

• The Reporting Persons may dispose of additional shares of Veradermics, Inc. depending on market conditions and other factors.

Key Dates

Recommendation

StockSavvy.ai recommends a 'hold' based on this filing. While the sale of shares by a significant holder could be a negative signal, the filing does not indicate any fundamental deterioration in the company's business or prospects. The price at which the shares were sold ($104.30) suggests a strong valuation at that time. The lack of disclosed plans for further negative actions, coupled with the possibility of future share disposals, warrants a cautious 'hold' stance pending further developments or clarity on SR One's ongoing strategy.

Keywords

Schedule 13D, Beneficial Ownership, Share Sale, Veradermics, SR One Capital Management, Investment Funds, Securities Trading